Protein kinases are enzymes that play a central role in cell signaling and regulation by adding a phosphate group to other proteins. Abnormal kinase activity is often associated with cancer, inflammatory disorders, and certain autoimmune diseases. Our dual kinase programs have the potential of achieving superior therapeutic outcomes by inhibiting two kinases in the same pathway.
The objective of dual kinase inhibitors is to target multiple signaling pathways for better disease treatment. Even if one major driver is identified, cells can often resist therapy by switching to alternative signaling. Dual targeting can improve treatment outcomes by suppressing signals and blocking bypass tracks that cause drug resistance.